These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30535358)

  • 41. Access to biologicals in Crohn's disease in ten European countries.
    Péntek M; Lakatos PL; Oorsprong T; Gulácsi L; Pavlova M; Groot W; Rencz F; Brodszky V; Baji P; Crohn's Disease Research Group
    World J Gastroenterol; 2017 Sep; 23(34):6294-6305. PubMed ID: 28974896
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biosimilar infliximab: an expert view.
    Genazzani A; Altomare G; Balato N; Cusano F; De Pità O; Loconsole F; Micali G; Piaserico S; Girolomoni G
    G Ital Dermatol Venereol; 2015 Aug; 150(4):449-59. PubMed ID: 25747260
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The nocebo effect: a clinical challenge in the era of biosimilars.
    Pouillon L; Socha M; Demore B; Thilly N; Abitbol V; Danese S; Peyrin-Biroulet L
    Expert Rev Clin Immunol; 2018 Sep; 14(9):739-749. PubMed ID: 30118338
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D.
    Yazdany J; Dudley RA; Lin GA; Chen R; Tseng CW
    JAMA; 2018 Sep; 320(9):931-933. PubMed ID: 30193264
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Switching to biosimilars: boon or bust?
    Mushtaq A; Kazi F
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):341-342. PubMed ID: 32183981
    [No Abstract]   [Full Text] [Related]  

  • 46. The Concept of Biosimilars: From Characterization to Evolution-A Narrative Review.
    Farhat F; Torres A; Park W; de Lima Lopes G; Mudad R; Ikpeazu C; Abi Aad S
    Oncologist; 2018 Mar; 23(3):346-352. PubMed ID: 29284760
    [TBL] [Abstract][Full Text] [Related]  

  • 47. IBD: Indication extrapolation for anti-TNF biosimilars.
    Vande Casteele N; Sandborn WJ
    Nat Rev Gastroenterol Hepatol; 2015 Jul; 12(7):373-4. PubMed ID: 26077557
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The use of biosimilars in paediatric inflammatory bowel disease.
    Jongsma MME; Vulto A; de Ridder L
    Curr Opin Pediatr; 2017 Oct; 29(5):560-565. PubMed ID: 28692448
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization.
    Danese S; Fiorino G; Michetti P
    J Crohns Colitis; 2014 Nov; 8(11):1548-50. PubMed ID: 25008477
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biosimilars in Crohn's Disease and Ulcerative Colitis.
    Wolf DC
    Inflamm Bowel Dis; 2016 Apr; 22(4):994-7. PubMed ID: 26933749
    [No Abstract]   [Full Text] [Related]  

  • 51. Friction in the Path to Use of Biosimilar Drugs.
    Frank RG
    N Engl J Med; 2018 Mar; 378(9):791-793. PubMed ID: 29490182
    [No Abstract]   [Full Text] [Related]  

  • 52. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overcoming barriers to biosimilars in inflammatory arthritis.
    Kay J
    Nat Rev Rheumatol; 2020 Feb; 16(2):65-66. PubMed ID: 31873190
    [No Abstract]   [Full Text] [Related]  

  • 54. Of patents and patent disputes - The TNFα patent files. Part 2: Enbrel, Remicade, Cimzia and Simponi.
    Storz U
    Hum Antibodies; 2018 Feb; 26(2):49-61. PubMed ID: 29439320
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn's Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability.
    Cozijnsen MA; Samsom JN; de Ridder L
    Paediatr Drugs; 2018 Feb; 20(1):19-28. PubMed ID: 29079905
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.
    Farkas K; Molnár T
    Immunotherapy; 2018 Feb; 10(2):107-117. PubMed ID: 29124994
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biosimilars-Curb Your Enthusiasm.
    Yang YT; Chen B; Bennett CL
    JAMA Oncol; 2017 Nov; 3(11):1467-1468. PubMed ID: 28594963
    [No Abstract]   [Full Text] [Related]  

  • 58. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.
    Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Are There Benefits and Risks to Biosimilars from a Patient Perspective?
    Kay J
    Rheum Dis Clin North Am; 2019 Aug; 45(3):465-476. PubMed ID: 31277756
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An update on biosimilar drugs for inflammatory bowel disease.
    Schreiber S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.